Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
By J. Orange, E. Hossny, C. Weiler, M. Ballow, M. Berger, F. Bonilla, R. Buckley, J. Chinen, Y. El-gamal, B. Mazer and 6 more. Journal of Allergy and Clinical Immunology, 2006
637 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Neurology
View Paper: https://www.semanticscholar.org/paper/45925844bc3c9b3ed88a3637394376c7c3eb1274
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Practice parameter for the diagnosis and management of primary immunodeficiency. (2015, background): “(B) The effectiveness of polyclonal human IgG for reducing serious bacterial infections in patients with XLA and those with common variable immunodeficiency (CVID) is well documented.(43,44) Therapeutic IgG is also used for combined defects with significantly impaired antibody production.”
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. (2013, background): “High dose intravenous immunoglobulin High dose intravenous immunoglobulin (IVIG) modulates the immune and inflammatory response by a variety of mechanisms and is used in a number of systemic autoimmune diseases.(170) Its use has been associated with improved left ventricular ejection fraction in chr”